Real‐World Multinational Survey of Chronic Inflammatory Demyelinating Polyneuropathy: Disease Characteristics and Therapeutic Landscape
Diagnostic delay and misdiagnoses were common occurrences across typical CIDP and variant CIDP. Despite the use of guideline treatments, there were unmet needs and a continued disease burden for patients.
Authors
- Luís Querol (ORCID: https://orcid.org/0000-0002-4289-8264)
- Jack Wright (ORCID: https://orcid.org/0000-0002-7380-9754)
- András Borsi (ORCID: https://orcid.org/0000-0003-4612-9830)
- Simon Rinaldi (ORCID: https://orcid.org/0000-0003-2039-3457)
- Wim Noël (ORCID: https://orcid.org/0000-0002-5988-4627)
- Gerd Meyer zu Hörste (ORCID: https://orcid.org/0000-0002-4341-4719)
- C. Gary (ORCID: https://orcid.org/0000-0002-6286-1370)
- Wisam Karmous
- Yasmin Taylor (ORCID: https://orcid.org/0000-0003-4454-5013)
- Jonathan de Courcy (ORCID: https://orcid.org/0000-0002-2100-5279)
- Giorgio Maria Boggia
Institutions
- Johnson & Johnson (United States) (US)
- Janssen (Belgium) (BE)
- Hospital de Sant Pau (ES)
- University of Oxford (GB)
- Adelphi Group (United Kingdom) (GB)
- University Hospital Münster (DE)
- Janssen (United Kingdom) (GB)
- Johnson & Johnson (Italy) (IT)
- Johnson & Johnson (United Kingdom) (GB)
Publication Details
- Journal
- Journal of the Peripheral Nervous System
- Published
- 2025-08-18
- DOI
- https://doi.org/10.1111/jns.70047
- Citations
- 3
- Primary Topic
- Peripheral Neuropathies and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 4.17
Funders
- Amgen
- Sanofi
- Biogen
- Alexion Pharmaceuticals
- Alnylam Pharmaceuticals
- CSL Behring
- Fundació la Marató de TV3
- Wellcome Trust
- GBS/CIDP Foundation International
- Argenx
- National Institute for Health and Care Research
- British Medical Association
- Pathological Society of Great Britain and Ireland
- University of Oxford
- Medical Research Council
- Instituto de Salud Carlos III